The Role of Inflammation in Cholestasis: Clinical and Basic Aspects

Hepatobiliary transport systems are essential for the uptake and excretion of a variety of compounds including bile acids. Disruption and dysregulation of this excretory pathway result in cholestasis, leading to the intrahepatic accumulation of bile acids and other toxic compounds with progression of liver pathology. Cholestasis induced by inflammation is a common complication in patients with extrahepatic infections or inflammatory processes, generally referred to as sepsis-associated cholestasis. Microbial products, including endotoxin, induce signaling pathways within hepatocytes either directly, or through activation of proinflammatory cytokines, leading to rapid and profound reductions in bile flow. The expression and function of key hepatobiliary transporters are suppressed in response to inflammatory signaling. These proinflammatory signaling cascades lead to repressed expression and activity of a large number of nuclear transcriptional regulators, many of which are essential for maintenance of hepatobiliary transporter gene expression. Interestingly, recently discovered molecular crosstalk between bile acid activated nuclear receptors and proinflammatory nuclear mediators may provide new means of understanding adaptive processes within liver. Inflammation-induced cholestasis and the effects of retained molecules in cholestasis on inflammatory signals are interwoven in the liver, providing potential opportunities for research and therapeutics.

[1]  Carol Soroka1,et al.  Organic Solute Transporter, OSTα-OSTβ: Its Role in Bile Acid Transport and Cholestasis , 2010 .

[2]  P. Meier,et al.  Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. , 2010, Seminars in liver disease.

[3]  Coen Paulusma1,et al.  Progressive Familial Intrahepatic Cholestasis Type 1 , 2010 .

[4]  M. Trauner,et al.  Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. , 2010, Seminars in liver disease.

[5]  J. Boyer,et al.  The Bile Salt Export Pump: Clinical and Experimental Aspects of Genetic and Acquired Cholestatic Liver Disease , 2010, Seminars in liver disease.

[6]  E. Jacquemin,et al.  The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. , 2010, Seminars in liver disease.

[7]  H. Jaeschke,et al.  Oxidative Stress and the Pathogenesis of Cholestasis , 2010, Seminars in liver disease.

[8]  C. Paulusma,et al.  Progressive familial intrahepatic cholestasis type 1. , 2010, Seminars in liver disease.

[9]  Ann M. Thomas,et al.  Genome‐wide tissue‐specific farnesoid X receptor binding in mouse liver and intestine , 2010, Hepatology.

[10]  M. Trauner,et al.  The new therapeutic frontier--nuclear receptors and the liver. , 2010, Journal of hepatology.

[11]  M. Lovell,et al.  Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. , 2010, The Journal of pediatrics.

[12]  P. Hirsova,et al.  Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats. , 2009, Biological & pharmaceutical bulletin.

[13]  A. Kosters,et al.  Redundant roles for cJun-N-terminal kinase 1 and 2 in interleukin-1beta-mediated reduction and modification of murine hepatic nuclear retinoid X receptor alpha. , 2009, Journal of hepatology.

[14]  Martin Wagner,et al.  New molecular insights into the mechanisms of cholestasis. , 2009, Journal of hepatology.

[15]  M. Trauner,et al.  Nuclear receptors as therapeutic targets in cholestatic liver diseases , 2009, British journal of pharmacology.

[16]  T. Miloh,et al.  The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor , 2008, Hepatology.

[17]  M. Trauner,et al.  Nuclear bile acid receptor farnesoid X receptor meets nuclear factor‐κB: New insights into hepatic inflammation , 2008, Hepatology.

[18]  B. M. Forman,et al.  Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.

[19]  A. Kosters,et al.  Bile acid transporters in health and disease , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  D. Brenner,et al.  Toll‐like receptors and adaptor molecules in liver disease: Update , 2008, Hepatology.

[21]  X. Chen,et al.  The immunobiology of cholangiocytes , 2008, Immunology and cell biology.

[22]  A. Sanyal,et al.  Sepsis and cholestasis. , 2008, Clinics in liver disease.

[23]  A. Cross,et al.  Review: From therapy to experimental model: a hundred years of endotoxin administration to human subjects , 2007, Journal of endotoxin research.

[24]  B. Carter,et al.  Intestinal Failure-Associated Liver Disease: Management and Treatment Strategies Past, Present, and Future , 2007, Seminars in liver disease.

[25]  M. Trauner,et al.  Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. , 2007, Biochimica et biophysica acta.

[26]  A. Sanyal,et al.  Sepsis‐induced cholestasis , 2007, Hepatology.

[27]  M. Trauner,et al.  Mechanisms of Disease: mechanisms and clinical implications of cholestasis in sepsis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[28]  B. Blumberg,et al.  Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. , 2006, The Journal of clinical investigation.

[29]  J. Folkman,et al.  Reversal of Parenteral Nutrition–Associated Liver Disease in Two Infants With Short Bowel Syndrome Using Parenteral Fish Oil: Implications for Future Management , 2006, Pediatrics.

[30]  M. Trauner,et al.  Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. , 2006, Molecular pharmaceutics.

[31]  Brady T. West,et al.  Pediatric Short Bowel Syndrome: Redefining Predictors of Success , 2005, Annals of surgery.

[32]  S. Glaser,et al.  The immunophysiology of biliary epithelium. , 2005, Seminars in liver disease.

[33]  F. Lammert,et al.  Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[34]  M. Trauner,et al.  Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. , 2005, Journal of clinical gastroenterology.

[35]  H. Denk,et al.  Cytokine‐independent repression of rodent Ntcp in obstructive cholestasis , 2005, Hepatology.

[36]  Micheline Piquette-Miller,et al.  The Involvement of the Pregnane X Receptor in Hepatic Gene Regulation during Inflammation in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[37]  X. Xia,et al.  Degradation of the Apical Sodium-dependent Bile Acid Transporter by the Ubiquitin-Proteasome Pathway in Cholangiocytes* , 2004, Journal of Biological Chemistry.

[38]  F. Lammert,et al.  Interleukin-6 regulates hepatic transporters during acute-phase response. , 2004, Biochemical and biophysical research communications.

[39]  S. Karpen,et al.  Endotoxin leads to rapid subcellular re-localization of hepatic RXRα: A novel mechanism for reduced hepatic gene expression in inflammation , 2004, Nuclear receptor.

[40]  Ning Li,et al.  Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[41]  Wei Wei,et al.  Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. , 2004, Free radical biology & medicine.

[42]  Y. Iwamoto,et al.  Interleukin‐1β represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells , 2004, Hepatology.

[43]  M. Ingelman-Sundberg,et al.  Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. , 2004, Biochemical pharmacology.

[44]  D. Häussinger,et al.  Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS , 2004, Biological chemistry.

[45]  M. Piquette-Miller,et al.  Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. , 2003, Journal of pharmaceutical sciences.

[46]  K. Isse,et al.  Lipopolysaccharide Activates Nuclear Factor-KappaB through Toll-Like Receptors and Related Molecules in Cultured Biliary Epithelial Cells , 2003, Laboratory Investigation.

[47]  C. Gartung,et al.  Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis , 2003, Hepatology.

[48]  K. Zatloukal,et al.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. , 2003, Journal of hepatology.

[49]  K. Feingold,et al.  Repression of Farnesoid X Receptor during the Acute Phase Response* , 2003, The Journal of Biological Chemistry.

[50]  M. Piquette-Miller,et al.  Inflammatory Cytokines, but Not Bile Acids, Regulate Expression of Murine Hepatic Anion Transporters in Endotoxemia , 2002, Journal of Pharmacology and Experimental Therapeutics.

[51]  K. Oien,et al.  Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha. , 2002, Liver.

[52]  P. Meier,et al.  Functional analysis of the rat bile salt export pump gene promoter. , 2002, European journal of biochemistry.

[53]  S. Karpen Nuclear receptor regulation of hepatic function. , 2002, Journal of hepatology.

[54]  K. Feingold,et al.  Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. , 2002, Biochemical and biophysical research communications.

[55]  K. Faber,et al.  Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump , 2002, Hepatology.

[56]  Paul T Tarr,et al.  Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.

[57]  M. Makishima,et al.  Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.

[58]  U. Beuers,et al.  Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. , 2001, Liver.

[59]  M W Whitehead,et al.  The causes of obvious jaundice in South West Wales: perceptions versus reality , 2001, Gut.

[60]  K. Zatloukal,et al.  Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases , 2001, Hepatology.

[61]  C. Deutschman,et al.  Intraabdominal sepsis down-regulates transcription of sodium taurocholate cotransporter and multidrug resistance-associated protein in rats. , 2000, Shock.

[62]  K. Feingold,et al.  The Acute Phase Response Is Associated with Retinoid X Receptor Repression in Rodent Liver* , 2000, The Journal of Biological Chemistry.

[63]  D. Mangelsdorf,et al.  Interleukin-1β Suppresses Retinoid Transactivation of Two Hepatic Transporter Genes Involved in Bile Formation* , 2000, The Journal of Biological Chemistry.

[64]  R. Stauber,et al.  Inflammation‐induced cholestasis , 1999, Journal of gastroenterology and hepatology.

[65]  P. Suter,et al.  Hepatic hemodynamics and cell functions in human and experimental sepsis. , 1999, Anesthesia and analgesia.

[66]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[67]  Y. Sugiyama,et al.  Kupffer cell-mediated down regulation of rat hepatic CMOAT/MRP2 gene expression. , 1999, Biochemical and biophysical research communications.

[68]  D. Häussinger,et al.  Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. , 1999, Gastroenterology.

[69]  J. Boyer,et al.  Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. , 1998, The Journal of clinical investigation.

[70]  D. Adams,et al.  Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro. , 1997, Proceedings of the Association of American Physicians.

[71]  M. Trauner,et al.  Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations. , 1997, The Yale journal of biology and medicine.

[72]  J. Boyer,et al.  Endotoxin impairs biliary glutathione and HCO3− excretion and blocks the choleretic effect of nitric oxide in rat liver , 1997, Hepatology.

[73]  G. Ramadori,et al.  Cytokines and the hepatic acute phase response , 1997, The Journal of pathology.

[74]  D. Beier,et al.  Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. , 1996, Gastroenterology.

[75]  F. Suchy,et al.  Multiple Factors Regulate the Rat Liver Basolateral Sodium-dependent Bile Acid Cotransporter Gene Promoter* , 1996, The Journal of Biological Chemistry.

[76]  D. Wilmore,et al.  THE SYSTEMIC INFLAMMATORY RESPONSE: PERSPECTIVE OF HUMAN ENDOTOXEMIA , 1996, Shock.

[77]  J. Corkery,et al.  Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. , 1996, Journal of pediatric surgery.

[78]  Peter Oelkers,et al.  Bile acid transporters , 1995, Current opinion in lipidology.

[79]  T. Yoshida,et al.  Endotoxin‐induced cytokine gene expression and excretion in the liver , 1994, Hepatology.

[80]  K Tanaka,et al.  Analysis of the rat hepatocyte nuclear factor (HNF) 1 gene promoter: synergistic activation by HNF4 and HNF1 proteins. , 1993, Nucleic acids research.

[81]  A. Johnson,et al.  Sepsis and jaundice. , 1993, Pediatrics.

[82]  W. Handrick,et al.  [Septicemia in the newborn]. , 1992, Krankenpflege Journal.

[83]  Y. Calmus,et al.  Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor–α production by monocytes , 1992, Hepatology.

[84]  M. Gore,et al.  Tumour necrosis factor, cholestatic jaundice, and chronic liver disease. , 1990, Gut.

[85]  D. Kufe,et al.  Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  F. Suchy,et al.  Bile salt metabolism in the first year of life. , 1982, The Journal of laboratory and clinical medicine.

[87]  S. Seifter,et al.  PROLONGED NEONATAL UNCONJUGATED HYPERBILIRUBINEMIA ASSOCIATED WITH BREAST FEEDING AND A STEROID, PREGNANE-3(ALPHA), 20(BETA)-DIOL, IN MATERNAL MILK THAT INHIBITS GLUCURONIDE FORMATION IN VITRO. , 1964, The Journal of clinical investigation.

[88]  A. Brown,et al.  Sepsis and jaundice in early infancy. , 1962, Pediatrics.

[89]  J. R. Wilkinson,et al.  AIDS TO BIOCHEMISTRY , 1960, The Ulster Medical Journal.

[90]  P. Hench Recent Investigations on Rheumatism and Arthritis in the United States * , 1940, Annals of the rheumatic diseases.

[91]  P. Hench EFFECT OF JAUNDICE ON CHRONIC INFECTIOUS (ATROPHIC) ARTHRITIS AND ON PRIMARY FIBROSITIS: FURTHER OBSERVATIONS; ATTEMPTS TO REPRODUCE THE PHENOMENON , 1938 .

[92]  F. Kuipers,et al.  Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis. , 2009, Frontiers in bioscience.

[93]  S. Teng,et al.  Regulation of transporters by nuclear hormone receptors: implications during inflammation. , 2008, Molecular pharmaceutics.

[94]  M. Graham,et al.  Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[95]  J. Boyer,et al.  Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[96]  A. Burns,et al.  Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. , 2006, The Journal of biological chemistry.

[97]  J. Chiang,et al.  Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. , 2006, Hepatology.

[98]  J. Kamps,et al.  Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats. , 2005, Journal of hepatology.

[99]  K. Zatloukal,et al.  Immunohistochemical detection of tumor necrosis factor-alpha, other cytokines and adhesion molecules in human livers with alcoholic hepatitis , 2005, Virchows Archiv A.

[100]  Ning Li,et al.  Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (oatp4; oatplb2; slc21a10) by lipopolysaccharide. , 2004, Molecular pharmacology.

[101]  F. Sladek,et al.  Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver. , 2001, Hepatology.

[102]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.